{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091205","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.105042+00:00","generated_at":"2026-05-31T12:40:36.042247+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Neumora Q2 net loss $58.7M; Phase 3 MDD data on track for Q4 2024","bullets":["Cash $371.6M as of June 30, 2024, expected to fund operations into 2026.","R&D expense $48.6M (up from $32.8M); G&A $15.2M (up from $9.3M).","Topline data from KOASTAL-1 Phase 3 study of navacaprant in MDD expected Q4 2024.","Phase 2 trial for navacaprant in bipolar depression initiated; Phase 1b of NMRA-511 in Alzheimer's agitation started.","NMRA-266 study on clinical hold; additional M4 PAM IND submission expected first half 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091205","json":"https://secwatch.observer/filing/0000950170-24-091205.json","markdown":"https://secwatch.observer/filing/0000950170-24-091205.md","text":"https://secwatch.observer/filing/0000950170-24-091205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000095017024091205/0000950170-24-091205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000095017024091205/nmra-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:40:36.042247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}